Drug Profile
LCAR L10D
Alternative Names: Anti-CD19/CD22 chimeric antigen receptor T cell therapy - Nanjing Legend Biotech; LCAR-L10DLatest Information Update: 28 Nov 2022
Price :
$50
*
At a glance
- Originator Nanjing Legend Biotech
- Developer Nanjing Legend Biotech; Second Affiliated Hospital of Xi'an Jiaotong University
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diffuse large B cell lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for phase-I development in Diffuse large B cell lymphoma(Refractory metastatic disease, Second-line therapy or greater) in China (IV, Infusion)
- 28 Nov 2022 No recent reports of development identified for phase-I development in Precursor-B-cell-lymphoblastic-leukaemia-lymphoma(In adolescents, Second-line therapy or greater, In adults) in China (IV, Infusion)
- 01 Nov 2021 Nanjing Legend Biotech Co and Second Affiliated Hospital of Xi'an Jiaotong University terminates a phase I clinical trial in Diffuse large B cell lymphoma (Second-line therapy or greater, Refractory metastatic disease) in China (IV),a s suitable patients were not recruited (NCT03593109)